Back to top
more

Arvinas (ARVN)

(Delayed Data from NSDQ)

$27.14 USD

27.14
840,209

-0.61 (-2.20%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $27.18 +0.04 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Strength Seen in Arvinas, Inc. (ARVN): Can Its 12% Jump Turn into More Strength?

by Zacks Equity Research

Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar?

by Zacks Equity Research

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Arvinas, Inc. (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

by Zacks Equity Research

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.

Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -132.98% and -96.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -22.62% and 2.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AstraZeneca (AZN) Q2 Earnings In Line, Vaccine Aids Sales

by Zacks Equity Research

AstraZeneca (AZN) surpasses second-quarter estimates for revenues while earnings meet estimates. Stock up in pre-market.

Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View

by Zacks Equity Research

Following a positive recovery from COVID-impacts, Alkermes (ALKS) beat both earnings and sales estimates in second-quarter 2021. The company also raised its guidance for 2021.

Recent Price Trend in Arvinas, Inc. (ARVN) is Your Friend, Here's Why

by Zacks Equity Research

Arvinas, Inc. (ARVN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View

by Zacks Equity Research

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021. Resultantly, the stock rises.

Analysts Estimate Arvinas, Inc. (ARVN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

All You Need to Know About Arvinas, Inc. (ARVN) Rating Upgrade to Buy

by Zacks Equity Research

Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arvinas, Inc. (ARVN) Moves 13% Higher: Will This Strength Last?

by Zacks Equity Research

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

by Zacks Equity Research

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas. The stock rises 9% post the announcement.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -7.69% and 41.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.92% and -70.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why

by Zacks Equity Research

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More

by Zacks Equity Research

Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.